You are here: Industry Insights > AGC Biologics

News List

AGC Biologics Completes PPQ Mfg. Campaign with Provention Bio contractpharma
August 27, 2020
AGC Biologics, achieved the on-schedule completion of a drug substance Process Performance Qualification (PPQ) campaign, focused on teplizumab (PRV-031) for partner Provention Bio.
AGC Biologics Enters CDMO Partnership with Ono Pharmaceuticals contractpharma
August 21, 2020
AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), is partnering with Ono Pharmaceutical Co., Ltd. to manufacture new biopharmaceuticals at the clinical development stage.
AGC Biologics, Novavax Expand Coronavirus Vax Pact contractpharma
August 12, 2020
Expands supply of Matrix-M adjuvant for Novavax’ coronavirus vaccine, NVX-CoV2373, from its facility in Seattle for U.S. supply.
AGC Biologics, Molecular Partners to Develop Anti-COVID-19 DARPin Program americanpharmaceuticalreview
July 20, 2020
AGC Biologics is partnering with clinical-stage biotech company Molecular Partners to develop a new class of custom-built protein therapeutics known as DARPin®.
AGC Biologics, Molecular Partners to Develop DARPin Anti-COVID-19 Program contractpharma
July 10, 2020
AGC Biologics will manufacture MP0420 at 100 liter and 1,000 liter scales for development and initial global supply.
AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program prnasia
July 09, 2020
Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) AGC Biologics is partnering with clinical-stage biotech company Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®. AGC Bio
Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing contractpharma
June 19, 2020
AGC Biologics scales up production to support Calypso’s clinical trials.
AGC Biologics Acquires AstraZeneca Facility contractpharma
June 05, 2020
Site located in Boulder, CO adds commercial-scale manufacturing capacity for its biopharmaceutical CDMO business.
AGC Biologics to produce Covid-19 vaccine adjuvant for Novavax pharmaceutical-technology
June 05, 2020
Novavax has selected AGC Biologics, a contract development and manufacturing organisation (CDMO), for large-scale manufacturing of an adjuvant for its Covid-19 vaccine candidate, NVX-CoV2373.
Novavax Selects AGC Biologics to Manufacture Novel COVID-19 Vax contractpharma
June 04, 2020
To provide large-scale GMP production of Matrix-M, the adjuvant component of Novavax’ coronavirus vaccine candidate, NVX-CoV2373.

Previous page 1 2 3 4 Next page